Leading biotech awarded second FDA Orphan Drug Designation to boost search for rare disease therapies pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Oxford-based SynaptixBio, whose aim is to find a treatment for TUBB4A-related leukodystrophies, has been awarded a £490,000 BioMedical Catalyst grant from Innovate UK to tackle less common variants of the disease. TUBB4A-related leukodystrophies are a group of rare neurodegenerative diseases primarily affecting .